Press Releases

Mediclinic Intnl plc - Director Declaration

RNS Number : 4969U
Mediclinic International plc
29 March 2019

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP


LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")


29 March 2019


Appointment of Danie Meintjes as designated Non-executive Director for engagement with the Company's workforce


The Company is pleased to announce the appointment of Danie Meintjes as designated Non-executive Director for engagement with the Company's workforce, in line with the provisions of the UK Corporate Governance Code (July 2018), with effect from 1 April 2019. Danie retired as Chief Executive Officer ("CEO") on 1 June 2018 and continues to serve as a Non-executive Director.  


Dr Edwin Hertzog, Group Chairman, said:


"I am pleased to announce that Danie Meintjes has been appointed as the designated Non-executive Director for engagement with the Company's workforce. As the former Group CEO and with his prior experience as Divisional HR Executive, Danie was closely involved with the Company's approach to engaging with, investing in and rewarding our people. With his wealth of knowledge and experience gained in different capacities over 30 years at Mediclinic, Danie is extremely well-positioned to engage effectively with our people. The Board of Directors welcomes Danie's appointment to this role and thanks him for taking on this additional responsibility".


Danie Meintjes said:


"I am delighted to be taking on this important role with specific responsibility for Mediclinic's workforce. Taking proper account of our peoples' interests, alongside those of other stakeholders, is an important part of our Board culture, and this will be strengthened further by creating a specific responsibility for workforce engagement on the Board, which I feel well-equipped to fulfil, given my many years of involvement with the Company".


About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.


Mediclinic comprises 76 hospitals and 28 clinics. Hirslanden operates 18 private hospitals and 4 clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 48 hospitals and 4 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 7 hospitals and 20 clinics with more than 900 inpatient beds in the United Arab Emirates.


Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.


For further information, please contact:

  Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569


Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

+44 (0)20 3786 8181


Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000


Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom


Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit